04/01/2026
DOCTOR-LED MEDICAL WEIGHT LOSS
GLP-1 medications are not just about weight loss.
When prescribed and monitored correctly, robust clinical evidence shows they can also improve key markers of metabolic health.
At Four18 Wellbeing, our programme is led by highly experienced NHS GPs, delivering medically supervised GLP-1 weight management with a focus on:
• Lowering blood pressure
• Reducing cholesterol
• Improving glycaemic control (HbA1c)
Large clinical trials have demonstrated that GLP-1 therapies such as semaglutide and tirzepatide are associated with:
– Significant reductions in HbA1c*
– Reductions in systolic blood pressure*
– Improvements in lipid profiles alongside weight reduction*
This is why we treat GLP-1 therapy as medical care, not a transactional prescription.
We have supported hundreds of patients through structured, doctor-led programmes with careful assessment, monitoring and follow-up. We also offer blood tests to define baseline results which can be repeated once treatment has finished.
Treatment is only offered where clinically appropriate, and individual results vary.
For more details:
📞 01332 404325
📧 info@four18wellbeing.com
*Evidence base (key studies):
• Semaglutide 2.4 mg and cardiometabolic outcomes – NEJM, STEP-1 Trial
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Tirzepatide and blood pressure / weight outcomes – NEJM, SURMOUNT-1
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• Glycaemic control (HbA1c) with GLP-1 therapies – NEJM, SURPASS-2
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
• GLP-1 receptor agonists and blood pressure reduction – Diabetes, Obesity & Metabolism (meta-analysis)
https://pubmed.ncbi.nlm.nih.gov/38505997/
• GLP-1 receptor agonists and lipid improvement – Meta-analysis
https://pubmed.ncbi.nlm.nih.gov/39666879/